Open Rheumatology Journal最新文献

{"title":"Tocilizumab in Large Vessel Vasculitis - Different Routes of Administration.","authors":"Marc Schmalzing,&nbsp;Ottar Gadeholt,&nbsp;Michael Gernert,&nbsp;Hans-Peter Tony,&nbsp;Eva C Schwaneck","doi":"10.2174/1874312901812010152","DOIUrl":"https://doi.org/10.2174/1874312901812010152","url":null,"abstract":"<p><strong>Background: </strong>Tocilizumab is increasingly used in the treatment of large vessel vasculitis with recent approval for giant cell arteritis.</p><p><strong>Objective: </strong>To determine the efficacy and safety of tocilizumab in large vessel vasculitis in a real-life setting using different routes of administration.</p><p><strong>Methods: </strong>Retrospective analysis of consecutive patients at a tertiary rheumatology department who received tocilizumab for large vessel vasculitis.</p><p><strong>Results: </strong>A total of 11 patients were treated with tocilizumab (8 giant cell arteritis, 2 large vessel vasculitis associated with rheumatoid arthritis, 1 Takayasu arteritis) after a median of 2 other steroid-sparing agents (range 1-4). Of these, 9 received tocilizumab as salvage therapy for active vasculitis and 2 due to the toxicity of their former steroid-sparing medication. After a mean follow-up of 23 months 7 patients were in remission as to vasculitis under a mean prednisolone dose of 1.7 ± 1.5 mg; one patient relapsed after long term remission having discontinued tocilizumab for elective surgery; one patient stopped tocilizumab after attributable infectious complications, and two patients died: one due to complications of vascular surgery, probably not attributable to tocilizumab; and the other due to sepsis secondary to sigmoiditis. Only 3 relapses occurred under continuous tocilizumab treatment. In all these 3 cases, renewed remission could be achieved by switching from subcutaneous (162 mg qw) to intravenous tocilizumab (8mg/kg q4w).</p><p><strong>Conclusion: </strong>Tocilizumab is efficacious in patients with large vessel vasculitis in a real-life situation. Safety appears to be acceptable, but infectious complications have to be considered. Intravenous tocilizumab may be used in patients who relapse under subcutaneous application.</p>","PeriodicalId":39124,"journal":{"name":"Open Rheumatology Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128017/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36523664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Assessment of Mean Platelet Volume in Patients with Systemic Lupus Erythematosus.","authors":"Lisandra Torres Hartmann, Ana Paula Alegretti, Alice Beatriz Mombach Pinheiro Machado, Eduardo Ferreira Martins, Rafael Mendonça da Silva Chakr, Andrese Aline Gasparin, Odirlei André Monticielo","doi":"10.2174/1874312901812010129","DOIUrl":"10.2174/1874312901812010129","url":null,"abstract":"<p><strong>Introduction: </strong>The Mean Platelet Volume (MPV) is a platelet activation biomarker that has been recently correlated with disease activity in SLE. We aimed to evaluate the MPV in patients with SLE comparing it with healthy individuals, to study the correlation between MPV and SLE Disease Activity Index (SLEDAI) in SLE patients and to analyze possible correlation between MPV and Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein (CRP), and complement components C3 and C4.</p><p><strong>Methods: </strong>This is a cross-sectional study in which 81 patients with SLE according to the American College of Rheumatology (ACR) diagnostic classification criteria and 58 healthy controls were included. Active disease was defined as SLEDAI>0.</p><p><strong>Results: </strong>Patients with active SLE had decreased MPV when compared to inactive disease group (10.0±0.7fL <i>vs</i>. 10.7±1.0fL, <i>p</i>=0.005, respectively) and when compared to control group (10.9±1.0fL, <i>p</i><0.001). Our study found a weak negative correlation between the SLEDAI and the MPV (r=-0.29, <i>p</i>=0.009). There was no correlation between MPV and CRP, ESR, C3 and C4. Also, no correlation between SLEDAI and CRP, ESR, C3 and C4 was found.</p><p><strong>Conclusion: </strong>MPV decreases in patients with active SLE and is inversely correlated with SLEDAI.</p>","PeriodicalId":39124,"journal":{"name":"Open Rheumatology Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6128018/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36523662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Vitamin D Serum Values between Rheumatoid Arthritis and Lupus Populations: An Observational Study.","authors":"Sahebari Maryam,&nbsp;Elham Atabati,&nbsp;Ravanshad Yalda","doi":"10.2174/1874312901812010124","DOIUrl":"https://doi.org/10.2174/1874312901812010124","url":null,"abstract":"RESEARCH ARTICLE Comparison of Vitamin D Serum Values between Rheumatoid Arthritis and Lupus Populations: An Observational Study Sahebari Maryam, Elham Atabati and Ravanshad Yalda Rheumatic Diseases Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran 2 Cellular and Molecular Research Center, School of Medicine, Birjand University of Medical Sciences, Birjand, Iran Clinical Research Development Unit, Ghaem Hospital, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran","PeriodicalId":39124,"journal":{"name":"Open Rheumatology Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120101/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36476681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune Regulatory Genes Are Major Genetic Factors to Behcet Disease: Systematic Review.","authors":"Yan Deng,&nbsp;Weifeng Zhu,&nbsp;Xiaodong Zhou","doi":"10.2174/1874312901812010123","DOIUrl":"https://doi.org/10.2174/1874312901812010123","url":null,"abstract":"Behcet's disease (BD) is a chronic refractory multi-system autoimmune disorder that occurs in a genetically susceptible host. Multiple genetic factors have been identified that may contribute to the pathogenesis of BD. The major genes with polymorphisms associated with BD include HLA-B and -A, CIITA, ERAP1, MICA, IL10, IL12A, IL12RB2, IL23R, MEFV, IRF8, TNFAIP3, REL, TLR4, NOD1,2, CCR1,CCR3, GIMAP1,2,4, KLRC4, STAT4, NCOA5, FOXP3, PSORS1C1, FUT2, UBAC2, SUMO4, ADO-EGR2, CEBPB-PTPN1, and JPKL-CNTN5. These genes encode proteins involved mainly in immune regulation and inflammation, and some in transcription and post-translational modification. A complete view of these BD-associated genes may provide a clue to this complex disease in terms of its pathogenesis and exploring potentially targeted therapies for BD.","PeriodicalId":39124,"journal":{"name":"Open Rheumatology Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1874312901812010123","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36476680","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pamidronate Treatment of Osteonecrosis of the Hip in Young Male.","authors":"A Lo Gullo,&nbsp;R Talotta,&nbsp;M Atteritano","doi":"10.2174/1874312901812010125","DOIUrl":"https://doi.org/10.2174/1874312901812010125","url":null,"abstract":"Background: Aseptic osteonecrosis of the hip is a clinical entity in which the necrotic process of the bone leads to pain and progressive disability. Objective: Pamidronate seems to reduce drastically the activation of the osteoclasts so that it can be useful only in the early stage of the disease, delaying the time of bone collapsing. Method: A 27-years-old male was treated with pamidronate for three consecutive days every four weeks. Results: After three months the patient came back at control showing a marked improvement in clinical condition, referred full recover from pain and dysmotility with improvement of the quality of life, which was confirmed by the result of MRI he had for control. Conclusion: We reported a case of aseptic osteonecrosis of the hip which was successfully treated pamidronate at dosage of 45 mg.","PeriodicalId":39124,"journal":{"name":"Open Rheumatology Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6118033/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36476682","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"MicroRNA155 Expression in Relation to BDCAF Scored Behçet's Disease in an Egyptian Patients' Sample.","authors":"Sally S Hassouna,&nbsp;Manal Y Tayel,&nbsp;Dalal M ElKaffash,&nbsp;Ahmed M Abdelhady,&nbsp;Eman H Elsayed","doi":"10.2174/1874312901812010115","DOIUrl":"https://doi.org/10.2174/1874312901812010115","url":null,"abstract":"<p><strong>Objective: </strong>To discover the possibility of using microRNA155 (miRNA155) expression level as a biomarker of Behçet's Disease (BD) activity or remission.</p><p><strong>Methods: </strong>Thirty BD patients' white blood cells (WBCs) miRNA155 expression was measured and compared to WBCs miRNA155 expression in 15 healthy subjects. Assessment of disease activity was done using Behçet's Disease Current Activity Form (BDCAF).</p><p><strong>Results: </strong>miRNA155 expression significantly decreases with the increase of BD activity scored by BDCAF.</p><p><strong>Conclusion: </strong>Increased miRNA155 may be used as a biomarker of BD remission and thus in the disease follow up. There could be a prospect of treating the disease <i>via</i> microRNA 155 effect enhancement.</p>","PeriodicalId":39124,"journal":{"name":"Open Rheumatology Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6110073/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36476679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multiple Membrane Transporters and Some Immune Regulatory Genes are Major Genetic Factors to Gout.","authors":"Weifeng Zhu,&nbsp;Yan Deng,&nbsp;Xiaodong Zhou","doi":"10.2174/1874312901812010094","DOIUrl":"https://doi.org/10.2174/1874312901812010094","url":null,"abstract":"<p><p>Gout is a common form of inflammatory arthritis caused by hyperuricemia and the deposition of Monosodium Urate (MSU) crystals. It is also considered as a complex disorder in which multiple genetic factors have been identified in association with its susceptibility and/or clinical outcomes. Major genes that were associated with gout include <i>URAT1, GLUT9, OAT4, NPT1 (SLC17A1), NPT4 (SLC17A3), NPT5 (SLC17A4), MCT9, ABCG2, ABCC4, KCNQ1, PDZK1, NIPAL1, IL1β, IL-8, IL-12B, IL-23R, TNFA, MCP-1/CCL2, NLRP3, PPARGC1B, TLR4, CD14, CARD8, P2X7R, EGF, A1CF, HNF4G and TRIM46, LRP2, GKRP, ADRB3, ADH1B, ALDH2, COMT, MAOA, PRKG2, WDR1, ALPK1, CARMIL (LRRC16A), RFX3, BCAS3, CNIH-2, FAM35A</i> and <i>MYL2-CUX2</i>. The proteins encoded by these genes mainly function in urate transport, inflammation, innate immunity and metabolism. Understanding the functions of gout-associated genes will provide important insights into future studies to explore the pathogenesis of gout, as well as to develop targeted therapies for gout.</p>","PeriodicalId":39124,"journal":{"name":"Open Rheumatology Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1874312901812010094","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36410266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sjögren's, Renal Tubular Acidosis and Osteomalacia - An Asian Indian Series.","authors":"Pulukool Sandhya,&nbsp;Debashish Danda,&nbsp;Simon Rajaratnam,&nbsp;Nihal Thomas","doi":"10.2174/1874312901812010114","DOIUrl":"https://doi.org/10.2174/1874312901812010114","url":null,"abstract":"","PeriodicalId":39124,"journal":{"name":"Open Rheumatology Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062904/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36410375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation Between Tumor Necrosis Factor-α Levels, Free Fatty Acid Levels, and Soluble Vascular Cell Adhesion Molecule-1 Levels in Rheumatoid Arthritis Patients.","authors":"Fazria Nasriati, Rudy Hidayat, Budiman Budiman, Ikhwan Rinaldi","doi":"10.2174/1874312901812010086","DOIUrl":"10.2174/1874312901812010086","url":null,"abstract":"<p><strong>Background: </strong>The mortality of Rheumatoid Arthritis (RA) is quite high, which is largely due to cardiovascular complications caused by endothelial dysfunction. One of the important inflammatory mediators that contribute to RA joints arthritis of TNF-α, also proven to play a role in endothelial dysfunction and play a role in increasing intracellular lipolysis, thus increasing circulating FFA levels.</p><p><strong>Objectives: </strong>To determine the correlation between TNF-α levels with VCAM-1 levels, correlation of TNF-α levels with FFA levels, and correlation of FFA levels with VCAM-1 levels.</p><p><strong>Methods: </strong>Cross sectional and retrospective design studies of adult RA patients treated at Cipto Mangunkusumo Hospital (RSCM), without metabolic disturbances, acute infection, cardiovascular disorders, or other autoimmune diseases. The cross-sectional data was collected from October to November 2017, while retrospective samples were collected since August 2016. TNF-α, VCAM-1, and FFA levels were assessed by serum blood test by ELISA method. Correlation analysis is done by Pearson analysis when the data distribution is normal and with Spearman analysis when the data distribution is not normal.</p><p><strong>Results: </strong>A total of 35 subjects were enrolled in the study. Most (97.1%) were women with an average age of 45.29 years, median disease duration of 48 months, and most had moderate disease activity (65.7%). No significant correlation was found between TNF-α levels and VCAM-1 levels (p = 0.677; r = +0.073). as well betwen TNF-α levels and FFA levels (p = 0.227; r = -0.21). The correlation between FFA and VCAM-1 levels showed significant correlation with negative correlation and weak correlation (p = 0.036; r = -0.355).</p><p><strong>Conclusions: </strong>(1) There was no correlation between TNF-α levels and VCAM-1 levels in RA patients; (2) There was no correlation between TNF-α levels and FFA levels in RA patients; (3) There was a negative correlation between FFA levels and VCAM-1 levels in RA patients.</p>","PeriodicalId":39124,"journal":{"name":"Open Rheumatology Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062898/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36410374","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune Regulatory Genes Are Major Genetic Factors to Behcet Disease: Systematic Review.","authors":"Yan Deng,&nbsp;Weifeng Zhu,&nbsp;Xiaodong Zhou","doi":"10.2174/1874312901812010070","DOIUrl":"https://doi.org/10.2174/1874312901812010070","url":null,"abstract":"<p><p>Behcet's disease (BD) is a chronic refractory multi-system autoimmune disorder that occurs in a genetically susceptible host. Multiple genetic factors have been identified that may contribute to the pathogenesis of BD. The major genes with polymorphisms associated with BD include HLA-B and -A, CIITA, ERAP1, MICA, IL10, IL12A, IL12RB2, IL23R, MEFV, IRF8, TNFAIP3, REL, TLR4, NOD1,2, CCR1,CCR3, GIMAP1,2,4, KLRC4, STAT4, NCOA5, FOXP3, PSORS1C1, FUT2, UBAC2, SUMO4, ADO-EGR2, CEBPB-PTPN1, and JPKL-CNTN5. These genes encode proteins involved mainly in immune regulation and inflammation, and some in transcription and post-translational modification. A complete view of these BD-associated genes may provide a clue to this complex disease in terms of its pathogenesis and exploring potentially targeted therapies for BD.</p>","PeriodicalId":39124,"journal":{"name":"Open Rheumatology Journal","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2018-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2174/1874312901812010070","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36365031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}